<DOC>
	<DOCNO>NCT01108341</DOCNO>
	<brief_summary>The primary objective study determine efficacy , measure overall response ( complete response + partial response ) bendamustine combination ofatumumab previously untreated patient indolent B-Cell Non-Hodgkin 's Lymphoma ( NHL ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Treatment With Bendamustine Combination With Ofatumumab Previously Untreated Patients With Indolent B-Cell Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Key The patient histopathologic confirmation one protocolspecific CD20+ Bcell nonHodgkin 's lymphoma . Tissue diagnostic procedure must perform within 6 month study entry biopsy material available review . The patient meet 1 follow needfortreatment criterion : 1 . Presence least 1 follow Bsymptoms : fever ( &gt; 38ºC ) unclear etiology night sweat weight loss great 10 % within prior 6 month 2. large tumor mass ( bulky disease ) characterize lymphomas diameter 3 cm 3 region lymphoma diameter 7 cm 1 region 3. presence lymphomarelated complication 4. hyperviscosity syndrome due monoclonal gammopathy The patient 's tumor verify CD20+ positive current previous excisional incisional tissue diagnostic procedure perform within 6 month study entry . The screen phase CT scan ( base local evaluation ) show : 2 clearly demarcated lesion large diameter ≥1.5 cm , 1 clearly demarcate lesion large diameter ≥2.0 cm The patient previously treat indolent lymphoma ( exception single course local radiation therapy exceed 2 adjacent lymph node region ) . The patient adequate hematologic hepatic function . The patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . The patient serum creatinine 2.0 mg/dL less creatinine clearance 30 mL/min , base CockcroftGault method , 24hour urine collection . The patient willing comply contraception requirement . Key The patient : Has small lymphocytic lymphoma mantle cell lymphoma . Has document history central nervous system ( CNS ) lymphomatous involvement . Has active malignancy , NHL , within past 3 year except localized prostate cancer without evidence bone metastasis , bladder , cervical , breast carcinoma insitu , nonmelanoma skin cancer . Has New York Heart Association ( NYHC ) Class III IV heart failure , uncontrolled arrythmias unstable angina , electrocardiographic evidence active ischemia active conduction system abnormality , myocardial infarction within last 6 month . Has know human immunodeficiency virus ( HIV ) infection . Has acute chronic hepatitis B hepatitis C infection . Is pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) Has serious uncontrolled , medical psychological disorder would impair ability subject receive study drug . Has receive another investigational agent within 30 day study entry . Has know hypersensitivity mannitol . Has Ann Arbor stage I disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>